{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:03:19Z","timestamp":1789578199594,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for Waldenstrom macroglobulinaemia (WM), while ibrutinib has emerged as an alternative. In the absence of randomised trials (RCTs) comparing these regimens, the optimal first-line treatment for WM remains uncertain. In this systematic review and meta-analysis, we sought to assess the efficacy and safety of first-line treatment regimens for WM. We searched key databases from January 2007 to March 2023, including phase II and III trials, including treatment-na\u00efve WM patients treated with rituximab-based regimens or ibrutinib. Response rates, progression-free survival (PFS), overall survival (OS), and toxicities were evaluated. Four phase III and seven phase II trials were included among 736 unique records. Pooled response rates from all comparative and non-comparative trials were 46%, 33% and 26% for bendamustine rituximab (BR), bortezomib-dexamethasone, cyclophosphamide, rituximab (BDRC) and ibrutinib rituximab (IR), respectively. Two-year pooled PFS was 89%, 81% and 82% with BR, BDRC and IR, respectively. Neuropathy was more frequent with bortezomib, while haematologic and cardiac toxicities were more common with chemo-immunotherapy and ibrutinib-based regimens respectively. Our findings suggest that BR yields higher response rates than bortezomib or ibrutinib-based combinations. RCTs comparing BR against emerging therapies, including novel Bruton Tyrosine Kinase Inhibitors, are warranted.<\/jats:p>","DOI":"10.1038\/s41408-023-00916-5","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T04:03:37Z","timestamp":1694059417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"13","author":[{"given":"Wee-Lee","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Cui Lian","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Jun Yan","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Mei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Hian Lee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-598X","authenticated-orcid":false,"given":"Joanne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-6137","authenticated-orcid":false,"given":"Anand D.","family":"Jeyasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miny","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-3537","authenticated-orcid":false,"given":"Sanjay","family":"de Mel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"916_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. Lyon: IARC; 2017."},{"key":"916_CR2","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D\u2019Sa S, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia. Lancet Haematol. 2020;7:e827\u2013e37.","journal-title":"Lancet Haematol"},{"key":"916_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0076-5","volume":"8","author":"MA Gertz","year":"2018","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia treatment algorithm 2018. Blood Cancer J. 2018;8:40.","journal-title":"Blood Cancer J."},{"key":"916_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ajh.21788","volume":"85","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol. 2010;85:670\u20134.","journal-title":"Am J Hematol"},{"key":"916_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","volume":"151","author":"A Agathocleous","year":"2010","unstructured":"Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2010;151:346\u201353.","journal-title":"Br J Haematol"},{"key":"916_CR6","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830\u20135.","journal-title":"J Clin Oncol"},{"key":"916_CR7","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","volume":"122","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Garc\u00eda-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122:3276\u201382.","journal-title":"Blood."},{"key":"916_CR8","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","volume":"25","author":"MA Dimopoulos","year":"2007","unstructured":"Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344\u20139.","journal-title":"J Clin Oncol"},{"key":"916_CR9","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.22.01805","volume":"41","author":"C Buske","year":"2023","unstructured":"Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mah\u00e9 B, et al. Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstr\u00f6m\u2019s macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia. J Clin Oncol. 2023;41:2607\u201316.","journal-title":"J Clin Oncol"},{"key":"916_CR10","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet."},{"key":"916_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37:984\u201391.","journal-title":"J Clin Oncol"},{"key":"916_CR12","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood.V122.21.3049.3049","volume":"122","author":"S Luminari","year":"2013","unstructured":"Luminari S, Goldaniga MC, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, et al. Bendamustine and rituximab combination in untreated indolent non follicular B-cell non-Hodgkin\u2019s lymphomas. A phase II study from the Fondazione Italiana Linfomi (INFL09). Blood. 2013;122:3049.","journal-title":"Blood."},{"key":"916_CR13","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018;378:2399\u2013410.","journal-title":"N Engl J Med"},{"key":"916_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ajh.26082","volume":"96","author":"MA Gertz","year":"2021","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96:258\u201369.","journal-title":"Am J Hematol"},{"key":"916_CR15","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ."},{"key":"916_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","volume":"128","author":"V Leblond","year":"2016","unstructured":"Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom\u2019s Macroglobulinemia. Blood. 2016;128:1321\u20138.","journal-title":"Blood."},{"key":"916_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.15044","volume":"180","author":"IW Flinn","year":"2018","unstructured":"Flinn I.W, Thompson D.S, Boccia R.V, Miletello G., Lipman A, Flora D, et al. Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. Br J Haematol. 2018;180:365\u2013373.","journal-title":"Br J Haematol"},{"key":"916_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.14826","volume":"179","author":"J Paludo","year":"2017","unstructured":"Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and\/or refractory and treatment-na\u00efve patients with Waldenstrom macroglobulinemia. Br J Haematol. 2017;179:98\u2013105.","journal-title":"Br J Haematol"},{"key":"916_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","volume":"129","author":"M Gavriatopoulou","year":"2017","unstructured":"Gavriatopoulou M, Garc\u00eda-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129:456\u20139.","journal-title":"Blood."},{"key":"916_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.21.00838","volume":"40","author":"C Buske","year":"2022","unstructured":"Buske C, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40:52\u201362.","journal-title":"J Clin Oncol"},{"key":"916_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjh.15718","volume":"186","author":"K Laribi","year":"2019","unstructured":"Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstr\u00f6m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186:146\u20139.","journal-title":"Br J Haematol"},{"key":"916_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.critrevonc.2016.06.004","volume":"105","author":"A Santos-Lozano","year":"2016","unstructured":"Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, Cristi-Montero C, Fiuza-Luces C, Pareja-Galeano H, et al. Response rate to the treatment of Waldenstr\u00f6m macroglobulinemia: a meta-analysis of the results of clinical trials. Crit Rev Oncol Hematol. 2016;105:118\u201326.","journal-title":"Crit Rev Oncol Hematol"},{"key":"916_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-138765","volume":"136","author":"Q Khurshid","year":"2020","unstructured":"Khurshid Q, Dar AJ, Mirza MA, Ahmad ME, Jaan A, Aamir S, et al. A systemic review on efficacy of ibrutinib-based regimens for the treatment of Waldenstrom macroglobulinemia. Blood. 2020;136:8\u20139.","journal-title":"Blood."},{"key":"916_CR24","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2147\/OTT.S191179","volume":"12","author":"YH Zheng","year":"2019","unstructured":"Zheng YH, Xu L, Cao C, Feng J, Tang HL, Shu MM, et al. Rituximab-based combination therapy in patients with Waldenstr\u00f6m macroglobulinemia: a systematic review and meta-analysis. Onco Targets Ther. 2019;12:2751\u201366.","journal-title":"Onco Targets Ther"},{"key":"916_CR25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/ajh.26552","volume":"97","author":"H Abushukair","year":"2022","unstructured":"Abushukair H, Syaj S, Ababneh O, Qarqash A, Schinke C, Thanendrarajan S, et al. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstr\u00f6m\u2019s macroglobulinemia: a systematic review and meta-analysis. Am J Hematol. 2022;97:942\u201350.","journal-title":"Am J Hematol"},{"key":"916_CR26","doi-asserted-by":"publisher","first-page":"7566","DOI":"10.1200\/JCO.2022.40.16_suppl.7566","volume":"40","author":"JP Abeykoon","year":"2022","unstructured":"Abeykoon JP, Kumar S, Castillo JJ, D\u2019Sa S, Kastritis E, Durot E, et al. Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenstr\u00f6m macroglobulinemia (WM): an international collaborative study. J Clin Oncol. 2022;40:7566. (16_suppl)","journal-title":"J Clin Oncol"},{"key":"916_CR27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMc1506192","volume":"373","author":"SP Treon","year":"2015","unstructured":"Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;373:584\u20136.","journal-title":"N Engl J Med"},{"key":"916_CR28","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/annonc\/mdy449","volume":"29","author":"L Marandino","year":"2018","unstructured":"Marandino L, La Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, et al. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. Ann Oncol. 2018;29:2288\u201395.","journal-title":"Ann Oncol."},{"key":"916_CR29","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","volume":"38","author":"SP Treon","year":"2020","unstructured":"Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, et al. Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38:1198\u2013208.","journal-title":"J Clin Oncol"},{"key":"916_CR30","doi-asserted-by":"publisher","first-page":"204062072198958","DOI":"10.1177\/2040620721989586","volume":"12","author":"I Ntanasis-Stathopoulos","year":"2021","unstructured":"Ntanasis-Stathopoulos I, Gavriatopoulou M, Fotiou D, Dimopoulos MA. Current and novel BTK inhibitors in Waldenstr\u00f6m\u2019s macroglobulinemia. Ther Adv Hematol. 2021;12:2040620721989586.","journal-title":"Ther Adv Hematol"},{"key":"916_CR31","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136:2038\u201350.","journal-title":"Blood."},{"key":"916_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.hoc.2018.05.011","volume":"32","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Dimopoulos MA. Proteasome inhibitors in Waldenstr\u00f6m macroglobulinemia. Hematol Oncol Clin North Am. 2018;32:829\u201340.","journal-title":"Hematol Oncol Clin North Am"},{"key":"916_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","volume":"15","author":"SP Treon","year":"2009","unstructured":"Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, et al. Lenalidomide and rituximab in Waldenstrom\u2019s macroglobulinemia. Clin Cancer Res. 2009;15:355\u201360.","journal-title":"Clin Cancer Res"},{"key":"916_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ajh.23620","volume":"89","author":"IM Ghobrial","year":"2014","unstructured":"Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. Am J Hematol. 2014;89:237\u201342.","journal-title":"Am J Hematol"},{"key":"916_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.21.01194","volume":"40","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2022;40:63\u201371.","journal-title":"J Clin Oncol"},{"issue":"19","key":"916_CR36","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"},{"issue":"21","key":"916_CR37","doi-asserted-by":"publisher","first-page":"438.","DOI":"10.1182\/blood.V120.21.438.438","volume":"120","author":"MA Dimopoulos","year":"2012","unstructured":"Dimopoulos MA, Roussou M, Kastritis E, Hadjiharissi E, Kyrtsonis M-C, Symeonidis A, et al. Primary Treatment of Waldenstrom\u2019s Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. Blood. 2012;120(21):438.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00916-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00916-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00916-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T05:07:03Z","timestamp":1700456823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00916-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00916-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}